Such drug-resistant mutations have witnessed a recent upsurge fueled by the growing interest in the development of second-generation ALK inhibitors such as ceritinib, alectinib, and brigatinib for treatment of advanced (metastatic), ALK-positive NSCLC patients who had no response with crizotinib treatment (Roskoski, 2017; Roskoski, 2021). This evidence concerns the gene ALK and non-small cell lung carcinoma.